Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSITION-T2D: Semaglutide + Basal Insulin vs MDI
NCT04538352Phase 4Completed
- Sponsor
- Cleveland Clinic
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Cleveland Clinic. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04538352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538352.